Evicenter
Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer
Manufacturer
Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP
Prescribing information
Datroway (opens in a new tab)
Questions
42
Last updated

All questions

Safety: Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer

10 questions · 3 sources

Monitoring

After a DATROWAY infusion, how long should patients be monitored?

Safety

What are the most common DATROWAY side effects in HR-positive, HER2-negative breast cancer?

How often did DATROWAY cause serious side effects in TROPION-Breast01?

DATROWAY vs chemotherapy: how common were Grade 3 or higher side effects (TROPION-Breast01)?

Can DATROWAY cause interstitial lung disease (ILD) or pneumonitis?

What eye side effects can DATROWAY cause?

“DATROWAY can cause ocular adverse reactions including dry eye, keratitis, blepharitis, meibomian gland dysfunction, increased lacrimation, conjunctivitis, and blurred vision. In patients with unresectable or metastatic breast cancer and other solid tumors, ocular adverse reactions occurred in 38% of patients treated with DATROWAY. Forty-two patients (3.1%) experienced Grade 3 ocular adverse reactions, which included keratitis and dry eye, and four patients (0.3%) experienced a Grade 4 ocular adverse reaction of keratitis, corneal epithelium defect, corneal lesion, and conjunctival hemorrhage. The most common (≥5%) ocular adverse reactions were dry eye (18%), keratitis (16%), increased lacrimation (6%), and conjunctivitis (5%). The median time to first onset for ocular adverse reactions was 2.3 months (range: 0.03 months to 30 months) and with a median duration of 2.3 months (range: 0.03 months to 19.5 months). Of the patients who experienced ocular adverse reactions, 39% had complete resolution, and 8% had partial improvement (defined as a decrease in severity by one or more grades from the worst grade at last follow up). Ocular adverse reactions led to dosage interruption in 4.3% of patients, dosage reductions in 2.8% of patients, and permanent discontinuation of DATROWAY in 0.9% of patients. Patients with clinically significant corneal disease were excluded from clinical studies.” (opens the source at this quote in a new tab)

How common are DATROWAY mouth sores (stomatitis)?

Safety management

How is DATROWAY ILD or pneumonitis managed?

Safety and prevention

Does DATROWAY require eye exams and eye drops?

How are DATROWAY mouth sores (stomatitis) prevented and managed?